#Israel #Herzliya #InterCure #Canndoc #Alexander Rabinovich

InterCure Appoints New Chairman: Alexander Rabinovich

InterCure Ltd., known for its operations under the Canndoc brand, has made significant leadership changes as it strives to solidify its position in the pharmaceutical cannabis market. As of February 13, 2025, Alexander Rabinovich will take over the role of Chairman of the Board, succeeding Ehud Barak, who has served in that capacity for six years.

Mr. Barak, who celebrated his 83rd birthday, has decided to step down to pursue personal interests after a commendable tenure. His leadership played a crucial role in shaping the company’s trajectory, especially during challenging periods, including recovery efforts following the recent war impacting operations in Israel.

Rabinovich, who has been the CEO of InterCure for the past five years, is credited with steering the company towards remarkable growth and establishing pivotal international partnerships that have bolstered its reputation in the burgeoning cannabis industry. During his leadership as CEO, InterCure achieved impressive financial milestones, including delivering profitable growth.

Under Rabinovich's guidance, the company plans to focus on completing the recovery of its Nir Oz facility, which has faced setbacks due to external conflicts. InterCure successfully raised approximately $18.2 million (NIS 66 million) to support the rebuilding efforts and will work to secure further compensation for losses incurred during the war. The recovery plan is essential for future expansions and will ensure that InterCure continues to provide high-quality medical cannabis to its patients.

In a statement, Mr. Barak reflected on his time with InterCure, expressing pride in the company's achievements and the critical contributions made to the industry. “Throughout my time with the Company, we have upheld the highest professional standards,” he noted. “I extend my deepest gratitude to Alex, the Board, and everyone who has been part of this journey.”

Rabinovich, on taking the reins, acknowledged the importance of Barak’s contributions and expressed a commitment to the company's future. “As we look ahead, we remain focused on completing the rehabilitation of our Nir Oz facility, which is ongoing and essential for our recovery,” he stated. The company will also seek additional funding and support from the Israeli government to offset war-related damages.

With the leadership transition, InterCure aims to strengthen its position in the global cannabis market, not only by enhancing operations domestically but also by expanding into international markets, including Germany, the UK, and Australia. The company is dedicated to ensuring that it meets the needs of patients needing access to pharmaceutical-grade cannabis products.

In summary, the appointment of Alexander Rabinovich marks a new chapter for InterCure as it navigates the complexities of international expansion and recovery from recent adversities, emphasizing its commitment to patient welfare and product quality. The leadership change reflects a strategic move to maintain growth and innovation in a rapidly evolving industry.